key: cord-0869798-dxf3qm70
authors: Balan, Shuba; Beauchamps, Laura; Gonzales-Zamora, Jose Armando; Vu, Christine; Amoros, Annette; Quiroz, Tanya; Stevenson, Mario; Sharkey, Mark; Andrews, David M.; Abbo, Lilian
title: Recovery does not always signal the end of the battle: A Case of Post SARS-CoV-2 Multisystem Inflammatory Syndrome in an Adult
date: 2021-03-17
journal: IDCases
DOI: 10.1016/j.idcr.2021.e01067
sha: a296f7971c7cf0d4365cdb84df5587c5840f7e4a
doc_id: 869798
cord_uid: dxf3qm70

We describe a case of SARS-CoV-2 post-infectious inflammatory syndrome in an adult who presented with multiorgan failure two months following his initial diagnosis of SARS-CoV-2 infection. This case highlights clinician’s early recognition of this devastating sequela and challenges in appropriate management of this patient.

Multisystem inflammatory syndrome can follow current or prior SARS-CoV-2 infection, with emerging reports of Kawasaki-like multisystem inflammatory syndrome described in adults [1] [2] [3] and the more recent case series of nine patients (officially reported) by the Centre for Disease Control and Prevention (CDC) [4] . We describe the clinical presentation, treatment, and response of an adult with history of SARS-CoV-2 infection presenting with multiorgan failure two months following recovery from acute illness with no preceding respiratory symptoms. We believe this is the first case in Miami, Florida. We aim to raise clinical awareness of this post infectious multisystem inflammatory sequelae which we believe is related to SARS-CoV-2 infection.

A 46-year-old man with obesity (body mass index 42kg/m2) presented to our emergency department (ED) in July 2020 with right lower extremity weakness, nausea and generalized weakness beginning 24 hours prior to arrival. He had been diagnosed with SARS-CoV-2 J o u r n a l P r e -p r o o f infection 60 days prior to this admission, after experiencing mild flu-like symptoms for a few days and was seen by his primary care physician. He was found to have positive total antibodies and two negative nasopharyngeal polymerase chain reaction (PCR) for SARS-CoV-2 on 4/24/2020 and 5/10/2020, which were confirmed by the Florida Department of Health. Upon hospital admission, he was alert and oriented to self, time and place, hypotensive with blood pressure 88/37 mmHg, and hypoxic with oxygen saturation 89% on nasal cannula at 3 L/min.

Physical exam was notable for bilateral rhonchi on auscultation of lungs with right lower extremity strength 3/5, no skin rashes evident. Initial labs revealed a negative nasopharyngeal PCR and a positive total antibody test for SARS-CoV-2. SARS-CoV-2 total antibodies were measured to be 238 signal/cut-off (s/co) ratio, and IgG of 11s/co ratio, both defined as high per our reference range (0.00-0.99). Inflammatory markers were elevated, ferritin 962 ng/mL, IL-6 121.09 pg/mL, C-reactive protein (CRP) 2.9 mg/dL, lactate dehydrogenase (LDH) 802 units/L with increase in procalcitonin 0.678 ng/mL. He was found to have acute kidney injury with an elevated creatinine of 4.10 mg/dL from baseline of 2.90 mg/dL, high anion gap metabolic acidosis and lactic acidosis. Chest x-ray showed left retrocardiac opacity with no evidence of overt edema. Electrocardiogram (EKG) demonstrated signs of non-ST elevation myocardial infarction (NSTEMI) with elevated troponin 0.282 ng/mL and brain natriuretic peptide (BNP) 3590 pg/mL. Transthoracic echocardiography (TTE) demonstrated grossly normal ejection fraction with borderline elevated right ventricular systolic pressure (RVSP). Computed tomography (CT) of the chest showed dependent ground glass opacities in bilateral upper lobes, right middle lobe and in bilateral lower lobes with a more confluent patchy airspace opacity noted in the left upper lobe. CT abdomen showed hepatic steatosis. There was concern for potential posterior circulation stroke as he was found to have right ataxia, mild right hemiparesis J o u r n a l P r e -p r o o f and left hemianesthesia; however, CT head was unremarkable. He continued to experience hypoxia while in the ED and required oxygen support with 6 liters of nasal cannula (O2 saturation fluctuating between 84-91%). On hospitalization day 1, chest x-ray revealed diffuse bilateral mixed interstitial and airspace opacities worsened in the right lung compared to admission The patient was tachypneic with worsening hypoxemia and required 40 liters/min high-flow nasal cannula (O2 saturation fluctuating between 85-99%) and was transferred to the Intensive Care Unit (ICU). He underwent invasive mechanical ventilation and was started on norepinephrine to maintain perfusion for possible septic shock. Additionally, he was initiated on intravenous ceftriaxone 2 gm daily, oral azithromycin 500 mg, and oral dexamethasone 6 mg daily, along with unfractionated heparin in a continuous infusion of 12 unit/kg/hr for suspected NSTEMI. A repeat nasopharyngeal SARS-CoV-2 PCR was performed and was negative. On were notable for ferritin >100,000 ng/mL and LDH > 12,000 units/L. Due to ongoing concern for MIS-A, SARS-CoV-2 RT PCR (plasma) was repeated and reported as below limit of detection. Whole genome sequencing of Spike (S) gene from BAL for suspected reinfection/false negative PCR was attempted but failed to detect the SARS CoV-2 RNA. On hospitalization day 9, the ICU team switched dexamethasone 6 mg to hydrocortisone 50mg q6h.

The patient continued to have severe refractory acidosis and hyperkalemia despite CVVH and suffered an arrhythmia on day 10 leading to his death. Hospital course with pertinent laboratory results summarized in Timeline ( Figure 1 ). Inflammatory markers trend over time and response to treatment depicted in Figure 2 .

Multisystem Inflammatory syndrome (MIS) can occur in patients with past mild or asymptomatic SARS-CoV-2 infection. Although no diagnostic criteria for MIS-A has been established, our adult patient had a clinical presentation consistent with the CDC [6] and WHO [7] J o u r n a l P r e -p r o o f criteria for MIS-C. He had more than one organ system involvement on admission (cardiac and renal) with positive serology test for SARS-CoV-2 and negative SARS-CoV-2 PCR from NP and BAL samples with laboratory evidence of severe inflammation and absence of severe respiratory illness prior to admission. Furthermore, our patient developed this multisystem involvement two months after the initial diagnosis of SARS-CoV-2 with no other proven etiology.

Clinically, vascular dysfunction related to SARS-Co-V-2 manifests beyond the lung in different ways, including deep venous thrombosis, pulmonary embolism, large arterial thrombosis, and multiorgan venous and arterial thromboses, and these manifestations have been attributed to factors such as hypoxemia, viral sepsis, immobility, and occasionally vasculitis. [8] Pulmonary venous thromboembolism well described in SARS-CoV-2 [9] [10] [11] could manifest with systemic emboli with organ ischemia and mimic vasculitis with similar presentation like our patient. This would be ideally confirmed with a CT pulmonary angiography which is gold standard, as our patient was hemodynamically unstable this was not performed. However, our patient empirically received anticoagulation for NSTEMI noted on EKG, that would have treated possible micro emboli/thrombus if indeed present. Potential vasculitic involvement of other organs such as heart, brain, kidneys and skin seemed less likely due to the absence of pericarditis on exam and TTE, no acute infarctions on CT brain or renal ultrasound and lack of skin lesions respectively. Additionally, autopsy would have enabled clarification on the likelihood of alternative etiologies of this presentation, unfortunately not performed.

The borderline elevated right ventricular systolic pressures on TTE along with elevated troponins could suggest early pulmonary hypertension related to thromboembolism however this could have alternate explanations as well such as sleep apnea (obesity with BMI >40) or heart failure (elevated BNP), and would warrant further diagnostics such as right heart catheterization which was not pursued in our case due to rapid clinical deterioration.

Another possibility is underlying malignancy which can also mimic vasculitis and manifest with multisystem thrombosis however CT chest, abdomen and pelvis were negative making it unlikely in this case.

Secondary hemophagocytic lymphohistiocytosis (sHLH) is shown to be associated with severe SARS-CoV-2 infection and can present with immune system activation rapidly progressing to multi-organ failure. [12, 13] Cardinal features of sHLH include unremitting fever, cytopenias, and hyperferritinaemia, pulmonary involvement including acute respiratory distress syndrome (ARDS) seen in approximately 50% of patients. [14] Although fever and elevated ferritin levels in our patient may be suggestive of HLH, absence of splenomegaly, labs without cytopenia, hypofibrinogenemia does not favor this diagnosis although should be interpreted with caution due to limitation in failing to obtain triglycerides and soluble IL-2 receptor levels. The treatment of HLH is based on HLH -2004 guidelines and modified based on underlying cause and course of disease. Given the parallel cytokine profile between HLH and SARS-CoV-2, our patient was treated for potential sHLH as he received high dose steroids on admission to mitigate the hyperactive immune system in addition to IL-6 inhibitor, unfortunately without significant benefit. Additionally, secondary HLH is associated with other viral illnesses, our patient was The specific pathogenic mechanisms of this delayed clinical presentation may be similar to MIS-C or sHLH, however remains unknown. In adult cohorts, it is known that those with severe disease have higher abundance, breadth and neutralizing activity of SARS-CoV-2 antibodies compared to adults who recovered from mild disease. Multiple factors such as specificity, concentration, affinity and isotype determine whether antibodies are protective vs pathogenic. [15] Though SARS-CoV-2 antibodies are presumed to have protective and neutralizing properties, elevated levels of non-neutralizing antibodies through mechanism of antibody dependent enhancement (ADE) of infection [15] known to occur in viral infections could have played a pathogenic role in the observed hyperinflammatory response. Additionally we speculate an autoimmune process promoting aberrant immune responses leading to systemic inflammation also observed in children with MIS-C. [16, 17] We believe that our patient's clinical picture was not consistent with cytokine storm because of the long timeframe between initial infection to development of symptoms.

To address the concern of possible re-infection and confirm PCR negativity on several nasal and BAL specimens, we attempted to sequence the Spike (S) gene from patient's BAL. Despite recovering ample specimens, no SARS CoV-2 RNA was detected that could be used as template for S gene sequencing.

The optimal treatment for SARS-CoV-2 associated multisystem inflammatory syndrome (MIS) remains unknown. Case reports have demonstrated a potential role for immunomodulator agents [1] [2] [3] 5] . For MIS-C treatment, corticosteroids, anakinra, IVIG, and tocilizumab have each been used with varying success in children; none have been compared head-to-head. [18] For adults, similar treatment modalities have been reported, with the exception of anakinra. [1] [2] [3] [4] We chose to initiate steroids based on the 'RECOVERY trial [19] and tocilizumab based on elevated IL-6 levels. Additionally, at the time, there were more studies to support tocilizumab compared to other non-steroid immunomodulators for mitigating hyperinflammation due to SARS-CoV-2. [20] [21] [22] 

This submission did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

The Imperfect Cytokine Storm

COVID-19 associated Kawasakilike multisystem inflammatory disease in an adult

An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19

Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection -United Kingdom and United States

An adult presentation consistent with PIMS-TS

COVID-19-Associated Multisystem Inflammatory Syndrome in Children -United States

Multisystem inflammatory syndrome in children and adolescents with COVID-19

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

COVID-19: consider cytokine storm syndromes and immunosuppression

Hemophagocytic syndrome and COVID-19

Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis

The potential danger of suboptimal antibody responses in COVID-19

Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19

COVID-New York approach

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease

The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

We like to thank CDC COVID-19 response team, Atlanta, GA for advice in management of this challenging case.

All authors declare "No Conflict" of interest related to this submission.J o u r n a l P r e -p r o o f